Artelo Biosciences (ARTL) Competitors $0.95 +0.00 (+0.17%) (As of 12/20/2024 05:40 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesSEC FilingsShort InterestTrends ARTL vs. TXMD, HCWB, MRNS, PMCB, SLGL, WENA, IPA, IMNN, AWH, and CRVOShould you be buying Artelo Biosciences stock or one of its competitors? The main competitors of Artelo Biosciences include TherapeuticsMD (TXMD), HCW Biologics (HCWB), Marinus Pharmaceuticals (MRNS), PharmaCyte Biotech (PMCB), Sol-Gel Technologies (SLGL), ANEW Medical (WENA), ImmunoPrecise Antibodies (IPA), Imunon (IMNN), Aspira Women's Health (AWH), and CervoMed (CRVO). These companies are all part of the "pharmaceutical products" industry. Artelo Biosciences vs. TherapeuticsMD HCW Biologics Marinus Pharmaceuticals PharmaCyte Biotech Sol-Gel Technologies ANEW Medical ImmunoPrecise Antibodies Imunon Aspira Women's Health CervoMed Artelo Biosciences (NASDAQ:ARTL) and TherapeuticsMD (NASDAQ:TXMD) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, media sentiment, institutional ownership, risk, dividends, community ranking, analyst recommendations, earnings and valuation. Do analysts recommend ARTL or TXMD? Artelo Biosciences currently has a consensus price target of $5.50, suggesting a potential upside of 480.41%. Given Artelo Biosciences' stronger consensus rating and higher possible upside, research analysts clearly believe Artelo Biosciences is more favorable than TherapeuticsMD.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Artelo Biosciences 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 3.33TherapeuticsMD 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Does the media prefer ARTL or TXMD? In the previous week, Artelo Biosciences and Artelo Biosciences both had 1 articles in the media. Artelo Biosciences' average media sentiment score of 0.00 equaled TherapeuticsMD'saverage media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Artelo Biosciences 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral TherapeuticsMD 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Does the MarketBeat Community favor ARTL or TXMD? TherapeuticsMD received 342 more outperform votes than Artelo Biosciences when rated by MarketBeat users. However, 75.86% of users gave Artelo Biosciences an outperform vote while only 58.93% of users gave TherapeuticsMD an outperform vote. CompanyUnderperformOutperformArtelo BiosciencesOutperform Votes4475.86% Underperform Votes1424.14% TherapeuticsMDOutperform Votes38658.93% Underperform Votes26941.07% Is ARTL or TXMD more profitable? Artelo Biosciences has a net margin of 0.00% compared to TherapeuticsMD's net margin of -207.77%. TherapeuticsMD's return on equity of -14.08% beat Artelo Biosciences' return on equity.Company Net Margins Return on Equity Return on Assets Artelo BiosciencesN/A -104.59% -94.06% TherapeuticsMD -207.77%-14.08%-9.61% Which has preferable valuation and earnings, ARTL or TXMD? Artelo Biosciences has higher earnings, but lower revenue than TherapeuticsMD. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioArtelo BiosciencesN/AN/A-$9.29M-$2.87-0.33TherapeuticsMD$1.60M8.02-$10.28MN/AN/A Which has more volatility and risk, ARTL or TXMD? Artelo Biosciences has a beta of 1.29, indicating that its stock price is 29% more volatile than the S&P 500. Comparatively, TherapeuticsMD has a beta of 1.12, indicating that its stock price is 12% more volatile than the S&P 500. Do institutionals & insiders have more ownership in ARTL or TXMD? 0.9% of Artelo Biosciences shares are held by institutional investors. Comparatively, 30.7% of TherapeuticsMD shares are held by institutional investors. 0.8% of Artelo Biosciences shares are held by insiders. Comparatively, 2.3% of TherapeuticsMD shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. SummaryArtelo Biosciences beats TherapeuticsMD on 8 of the 14 factors compared between the two stocks. Ad Brownstone ResearchMedia Humiliated: Demo of Elon’s Tech Proves They’re WrongElon Musk believes his new AI product will be worth an incredible $9 trillion. But the mainstream media is not buying it.Click here to watch this demo and decide for yourself. Get Artelo Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for ARTL and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ARTL vs. The Competition Export to ExcelMetricArtelo BiosciencesPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$3.06M$6.57B$5.14B$9.08BDividend YieldN/A3.00%5.09%4.23%P/E Ratio-0.3310.5990.1317.20Price / SalesN/A196.061,117.09117.04Price / CashN/A57.1643.1037.85Price / Book0.235.094.784.78Net Income-$9.29M$151.83M$120.31M$225.60M7 Day Performance-14.63%-2.14%-1.92%-1.23%1 Month Performance-14.63%-4.56%13.65%0.46%1 Year Performance-31.33%8.87%28.34%15.24% Artelo Biosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ARTLArtelo Biosciences2.072 of 5 stars$0.95+0.2%$5.50+480.4%-31.3%$3.06MN/A-0.335News CoverageTXMDTherapeuticsMD0.4365 of 5 stars$1.18-3.4%N/A-53.8%$13.59M$1.30M0.00420Analyst ForecastGap UpHCWBHCW Biologics0.406 of 5 stars$0.36+0.1%N/A-60.4%$13.52M$3.50M-0.3640Gap DownMRNSMarinus Pharmaceuticals4.3176 of 5 stars$0.24-8.6%$4.79+1,893.2%-97.6%$13.25M$31.47M-0.10110Analyst ForecastNews CoveragePMCBPharmaCyte Biotech0.4217 of 5 stars$1.67-2.9%N/A-24.8%$12.83MN/A2.612Earnings ReportSLGLSol-Gel Technologies2.4245 of 5 stars$0.45-5.3%$5.00+1,000.6%-66.5%$12.66M$1.55M-1.3650WENAANEW MedicalN/A$0.73-0.5%N/AN/A$12.51MN/A0.00N/AGap UpIPAImmunoPrecise Antibodies2.9227 of 5 stars$0.42+4.4%$5.00+1,087.4%-69.5%$12.14M$24.07M-0.5280News CoverageIMNNImunon2.3546 of 5 stars$0.84-1.1%$20.50+2,355.1%+9.2%$12.11M$500,000.00-0.4533Analyst ForecastNews CoverageGap UpAWHAspira Women's Health1.218 of 5 stars$0.71-5.2%$4.40+519.1%-69.7%$11.85M$9.15M-0.62110Analyst ForecastCRVOCervoMed2.1768 of 5 stars$1.92+1.1%$42.00+2,087.5%-67.1%$11.85M$7.14M0.004Analyst DowngradeAnalyst RevisionHigh Trading Volume Related Companies and Tools Related Companies TherapeuticsMD Alternatives HCW Biologics Alternatives Marinus Pharmaceuticals Alternatives PharmaCyte Biotech Alternatives Sol-Gel Technologies Alternatives ANEW Medical Alternatives ImmunoPrecise Antibodies Alternatives Imunon Alternatives Aspira Women's Health Alternatives CervoMed Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:ARTL) was last updated on 12/22/2024 by MarketBeat.com Staff From Our PartnersDid You See Trump’s Bombshell Exec. Order 001?Starting with what I call Exec. Order 001. It’s a bombshell law that I believe Trump will sign within minut...Banyan Hill Publishing | SponsoredWARNING: “Buffett Indicator” flashing for first time in 50 yearsWarren Buffett has sold a staggering $97 billion worth of stocks this year... But why? Our research indi...Behind the Markets | SponsoredYour bank is lying to you.You might think you have your money in a high-yield savings account, but do you really? The national average A...MyBankTracker | SponsoredRare "crisis signal" triggers for third time in U.S. marketA rare pattern has just repeated for the third time in U.S. history. The last two times this happened, the...Stansberry Research | SponsoredAI breakthrough about to upend industryEveryone is talking about AI right now. The talk has been endless ever since ChatGPT was released to the m...Porter & Company | SponsoredCould This Tiny Device Help You Make an Extra $30k a Year?I believe it’s going to power Elon Musk’s next AI revolution… A revolution he believes will be worth more t...Brownstone Research | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowAltcoin season moves fast, and those who hesitate are left behind. The window is closing.Crypto Swap Profits | SponsoredHOTTEST TRADER IN AMERICA 🔥🔥🔥Ready for a rocket ride this weekend? After alerting his readers to a tiny $2 stock called Bright Minds Bio...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Artelo Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Artelo Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ARTL Stock Alerts